

# PD-L1 Testing

## SCL Otago/Southland



Southern Community Laboratories Ltd. (SCL) has been offering Ancillary Testing for a number of solid tumour and haematological malignancies. From 23<sup>rd</sup> October 2018, **PD-L1** immunohistochemistry for metastatic malignancies outside the Non-Small Cell Lung Cancer (NSCLC) setting will be offered.

SCL has been performing PD-L1 immunohistochemistry for Non-Small Cell Lung Cancer (NSCLC) since June 2017 and has five experienced pathologists trained in scoring Tumour Proportion Score (TPS) in this setting. PD-L1 immunohistochemistry is now being offered for Urothelial Carcinoma (UC) and Gastric Carcinoma (GC) using a Combined Proportion Score (CPS). Future indications, pending MedSafe approval, include Cervical Carcinoma and Head and Neck Squamous Cell Carcinoma

### **Methodology**

PD-L1 immunohistochemistry (performed on FFPE sections using Roche clone SP263 using Ventana Optiview DAB detection system). Note: Agilent clone 22C3 using Dako Autostainer Link 48 is currently the only validated clone for PD-L1 CPS testing and harmonization data with other antibodies is in progress. The Roche clone, however has excellent comparison data (and is validated) in the setting of NSCLC.

### **Referral and sample requirements**

Pathology laboratory to send the below:

1. 4x slides of 4 micron sections placed at the upper end of coated slides undried (freshly cut FFPE tissue - 100 cells required)
2. Copy of the original pathology report from source lab (including specimen type, date and time collected, laboratory specimen number)
3. PD-L1 request form completed by referring oncologist.  
([https://www.sclabs.co.nz/images/docs/PDL1\\_Request.pdf](https://www.sclabs.co.nz/images/docs/PDL1_Request.pdf))

Address:

Anatomical Pathology - Level 2  
Southern Community Laboratories Ltd (Dunedin), Plunket House  
472 George Street, Dunedin, 9016

### **Consent and payment form**

See [https://www.sclabs.co.nz/images/docs/PDL1\\_Consent.pdf](https://www.sclabs.co.nz/images/docs/PDL1_Consent.pdf)

### **Reporting**

- Expected turnaround time: 2 working days upon receipt of sample.
- Tumour Proportion Score (TPS) for Non-Small Cell Lung Cancer.
- Combined Proportion Score (CPS) including referral cut-off points for Urothelial Carcinoma, Gastric Carcinoma, Cervical Carcinoma, Head and Neck Squamous Cell Carcinoma

### **Enquiries**

Dr Michael Lau ([michael.lau@sclabs.co.nz](mailto:michael.lau@sclabs.co.nz); 03-4748322)

Dr Martha Nicholson ([martha.nicholson@sclabs.co.nz](mailto:martha.nicholson@sclabs.co.nz); 03-4748319)